The short-and long-term outcomes of pancreaticoduodenectomy for cancer in child a patients are acceptable: A patient-control study from the Surgical French Association report for pancreatic surgery

Journal of Surgical Oncology

Volumn 111, Issue 6, 2015, Pages 776-783

  Regimbeau, Jean Marc ^a   Rebibo, Lionel ^a   Dokmak, Safi ^b   Boher, Jean Marie ^c   Sauvanet, Alain ^b   Chopin Laly, Xavier ^d   Adham, Mustapha ^d   Lesurtel, Mickaël ^e   Bigourdan, Jean Marc ^f   Truant, Stéphanie ^g   Pruvot, François René ^g   Ortega Deballon, Pablo ^h   Paye, François ⁱ   Bachellier, Philippe ^j   Delpero, Jean Robert ^c  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b BEAUJON HOSPITAL   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITÉ DE LYON   (France)

^g UNIV LILLE   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j UNIVERSITÉ DE STRASBOURG   (France)

more..

Author keywords

adenocarcinoma; Child A; cirrhosis; liver failure; pancreatoduodenectomy

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL MORTALITY; TREATMENT OUTCOME; ADENOCARCINOMA; ADVERSE EFFECTS; CASE CONTROL STUDY; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; CONTRAINDICATIONS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OPERATION DURATION; OPERATIVE BLOOD LOSS; PANCREATIC FISTULA; PANCREATIC NEOPLASMS; PORTAL HYPERTENSION; SEVERITY OF ILLNESS INDEX; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OPERATIVE TIME; PANCREATIC FISTULA; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84928137963     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23856     Document Type: Article

References (39)

1. Csikesz NG, Nguyen LN, Tseng JF, et al.: Nationwide volume and mortality after elective surgery in cirrhotic patients. J Am Coll Surg. 2009; 208: 96-103.
2. Mansour A, Watson W, Shayani V, et al.: Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997; 122: 730-735.
3. Hurst RD, Butler BN, Soybel DI, et al.: Management of groin hernias in patients with ascites. Ann Surg 1992; 216: 696-700.
4. Puggioni A, Wong LL,: A metaanalysis of laparoscopic cholecystectomy in patients with cirrhosis. J Am Coll Surg 2003; 197: 921-926.
5. Gervaz P, Pak-art R, Nivatvongs S, et al.: Colorectal adenocarcinoma in cirrhotic patients. J Am Coll Surg 2003; 196: 874-879.
6. Mariette C,: Is there a place for esogastric cancer surgery in cirrhotic patients. Ann Surg Oncol 2008; 15: 680-682.
7. Sener SF, Fremgen A, Menck HR, et al.: Pancreatic cancer: a report of treatment and survival trends for 100 1999; 189: 1-7.
8. McPhee JT, Hill JS, Whalen GF, et al.: Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 2007; 246: 246-253.
9. Turrini O, Paye F, Bachellier P, et al.: Pancreatectomy for adenocarcinoma in elderly patients: postoperative outcomes and long term results: a study of the French Surgical Association. Eur J Surg Oncol. 2013; 39: 171-178.
10. Nikfarjam M, Sehmbey M, Kimchi ET, et al.: Additional organ resection combined with pancreaticoduodenectomy does not increase postoperative morbidity and mortality. J Gastrointest Surg 2009; 13: 915-921.
11. Schwartz SI,: Biliary tract surgery and cirrhosis: a critical combination. Surgery. 1981; 90: 577-583.
12. Gil A, Martínez-Regueira F, Hernández-Lizoain JL,: The role of transjugular intrahepatic portosystemic shunt prior to abdominal tumoral surgery in cirrhotic patients with portal hypertension. Herníndez-Lizoain JL 2004; 30: 46-52.
13. Sethi H, Srinivasan P, Marangoni G, et al.: Pancreaticoduodenectomy with radical lymphadenectomy is not contraindicated for patients with established chronic liver disease and portal hypertension. Hepatobiliary Pancreat Dis Int 2008; 7: 82-85.
14. Fuks D, Sabbagh C, Yzet T, et al.: Cirrhosis should not be considered as an absolute contraindication for pancreatoduodenectomy. Hepatogastroenterology 2012; 59: 881-883.
15. Warnick P, Mai I, Klein F, et al.: Safety of pancreatic surgery in patients with simultaneous liver cirrhosis: a single center experience. Pancreatology 2011; 11: 24-29.
16. El Nakeeb, Sultan A, Salah AM, et al.: Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy. World J Gastroenterol. 2013; 19: 7129-7137.
17. Delpero JR, Paye F, Bachellier P.,: Cancer du Pancréas. Monographies de l'association francaise de Chirurgie. 2010, Arnette, Wolters Kluwer France.
18. Anthony PP, Ishak KG, Nayak NC, et al.: The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working patients sponsored by the World Health Organization. J Clin Pathol 1978; 31: 395-414.
19. Child CG, Turcotte JG.,: Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.
20. Pugh RN, Murray-Lyon IM, Dawson JL, et al.: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
21. Wiesner R, Edwards E, Freeman R, et al.: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
22. S. Balzan, J. Belghiti, O. Farges, et al.: The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 2005; 242: 824-828.
23. Ishizawa T, Hasegawa K, Kokudo N, et al.: Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg 2009; 144: 46-51.
24. Bassi C, Dervenis C, Butturini G, et al.: Postoperative pancreatic fistula: an international study patients (ISGPF) definition. Surgery 2005; 138: 8-13.
25. Dindo D, Demartines N, Clavien PA.,: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
26. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-55.
27. Sabbagh C, Fuks D, Regimbeau JM.,: Non-hepatic gastrointestinal surgery in patients with cirrhosis. J Visc Surg. 2014; 151: 203-11.
28. C. Liu, Z. Du, C. Lou, et al.: Enteral nutrition is superior to total parenteral nutrition for pancreatic cancer patients who underwent pancreaticoduodenectomy. Asia Pac J Clin Nutr 2011; 20: 154-160.
29. Braga M, Gianotti L, Radaelli G, et al.: Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial. Arch Surg 1999; 134: 428-433.
30. Sirinek KR, Burk RR, Brown M, et al.: Improving survival in patients with cirrhosis undergoing major abdominal operations. Arch Surg 1987; 122: 271-273.
31. Martinez JL, Rivas H, Delgado S, et al.: Laparoscopic-assisted colectomy in patients with liver cirrhosis. Surg Endosc 2004; 18: 1071-1074.
32. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
33. D'Amico G, Garcia-Tsao G, Pagliaro L.,: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44: 217-231.
34. Y. Zhang, Y. Gu, T. Guo, et al.: Perioperative immunonutrition for gastrointestinal cancer: A systematic review of randomized controlled trials. Surg Oncol. 2012; 21: e87-e95.
35. Cerantola Y, Hübner M, Grass F, et al.: Immunonutrition in gastrointestinal surgery. Br J Surg. 2011; 98: 37-48.
36. Lim C, Dokmak S, Cauchy F, et al.: Selective policy of no drain after pancreaticoduodenectomy is a valid option in patients at low risk of pancreatic fistula: a patients-control analysis. World J Surg 2013; 37: 1021-1027.
37. Mehta VV, Fisher SB, Maithel SK, et al.: Is it time to abandon routine operative drain use? A single institution assessment of 709 consecutive pancreaticoduodenectomies. J Am Coll Surg 2013; 216:635-42; discussion 642-644.
38. Kawai M, Tani M, Terasawa H, et al.: Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for 104 consecutive patients. Ann Surg. 2006; 244: 1-7.
39. Murakami Y, Uemura K, Sudo T, et al.: Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. J Surg Oncol 2013; 107: 414-421.